Etripamil

Unassigned

New Medicines

Paroxysmal supraventricular tachycardia (SVT), including AV nodal reentrant tachycardia (AVNRT), AV reentrant tachycardia (AVRT)

Information

New molecular entity
Milestone Pharmaceuticals
Milestone Pharmaceuticals

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Calcium-channel blocker, short acting
Prevalence of all SVT is about 2 in 1000, with AVNRT being the most common type. Frequency and duration of episodes vary widely; they may be minimally symptomatic or cause syncope [2].
Paroxysmal supraventricular tachycardia (SVT), including AV nodal reentrant tachycardia (AVNRT), AV reentrant tachycardia (AVRT)
Intranasal